Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2020 | PET/CT with bone marrow techniques as a measure of MRD in MM patients

Elena Zamagni • 12 Jun 2020
EHA 2020
Multiple Myeloma Carfilzomib Cyclophosphamide Lenalidomide
FORTE

Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, discusses the benefit of PET/CT in combination with bone marrow analysis as a measure of minimal residual disease (MRD) in newly diagnosed transplant-eligible multiple myeloma (MM) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Elena Zamagni

A project to improve the understanding of disease biology and treatment outcomes in myeloma
1:34
A project to improve the understanding of disease biology and treatment outcomes in myeloma
Elena Zamagni • 9 Dec 2024
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma
1:39
SRI results from MajesTEC-4: Tec-Len or Tec alone as maintenance therapy in newly diagnosed myeloma
Elena Zamagni • 9 Dec 2024
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies
0:57
The future of myeloma: the potential role of MRD-driven therapy de-escalation strategies
Elena Zamagni • 9 Dec 2024
Patient selection for selinexor
0:35
Patient selection for selinexor
Elena Zamagni • 24 Oct 2024

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Elena Zamagni • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Elena Zamagni • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Elena Zamagni • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Elena Zamagni • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals